文献速递膀胱癌与上尿路尿路上皮癌

预防性使用生物补片在回肠导管术中的随机临床试验(PUBMIC)

Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial.
PubMed 文献 · J Urol · 2024-04-15

这项3期随机对照试验纳入146例接受膀胱切除和回肠导管术的患者,1:1随机接受FlexHD预防性生物补片(腹腔内sublay技术)或标准回肠导管术。中位随访24个月,补片组与对照组影像学造口旁疝发生率无显著差异,无明确补片相关不良事件,结论为生物补片安全但术后2年内无显著保护作用。

要点

  • 生物补片组与对照组影像学造口旁疝无显著差异(18例 vs 19例)。
  • 两组临床造口旁疝均为8例,补片相关不良事件未报告。
  • 补片组中位手术时间延长31分钟,但无统计学显著差异(363 vs 332分钟,P=.16)。

核心结论

  • 在回肠导管构建时使用生物补片是安全的,但术后2年内无显著保护作用。

研究设计与样本

  • 3期随机对照试验(NCT02439060),纳入2015年至2021年在南加州大学接受膀胱切除和回肠导管术的146例患者,1:1随机接受FlexHD预防性生物补片(腹腔内sublay技术)或标准回肠导管术。
  • 随访为每4至6个月进行体格检查和CT,直至2年。

主要发现

  • 中位随访24个月,影像学造口旁疝在37例患者中检出(补片组18例 vs 对照组19例),临床造口旁疝在16例患者中检出(两组各8例)。
  • 影像学造口旁疝和临床造口旁疝的中位检出时间分别为8.3个月和15.5个月。
  • 补片组和对照组1年影像学无造口旁疝生存率分别为74% vs 75%,2年分别为69% vs 62%。
  • 补片组中位手术时间延长31分钟,但无统计学显著差异(363 vs 332分钟,P=.16)。
  • 5例患者(补片组3例,对照组2例)需要手术修复造口旁疝;未报告明确的补片相关不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the effect of prophylactic biologic mesh on parastomal hernia (PSH) development in patients undergoing cystectomy and ileal conduit (IC). MATERIALS AND METHODS: This phase 3, randomized, controlled trial (NCT02439060) included 146 patients who underwent cystectomy and IC at the University of Southern California between 2015 and 2021. Follow-ups were physical exam and CT every 4 to 6 months up to 2 years. Patients were randomized 1:1 to receive FlexHD prophylactic biological mesh using sublay intraperitoneal technique vs standard IC. The primary end point was time to radiological PSH, and secondary outcomes included clinical PSH with/without surgical intervention and mesh-related complications. RESULTS: The 2 arms were similar in terms of baseline clinical features. All surgeries and mesh placements were performed without any intraoperative complications. Median operative time was 31 minutes longer in patients who received mesh, yet with no statistically significant difference (363 vs 332 minutes, P = .16). With a median follow-up of 24 months, radiological and clinical PSHs were detected in 37 (18 mesh recipients vs 19 controls) and 16 (8 subjects in both arms) patients, with a median time to radiological and clinical PSH of 8.3 and 15.5 months, respectively. No definite mesh-related adverse events were reported. Five patients (3 in the mesh and 2 in the control arm) required surgical PSH repair. Radiological PSH-free survival rates in the mesh and control groups were 74% vs 75% at 1 year and 69% vs 62% at 2 years. CONCLUSIONS: Implementation of biologic mesh at the time of IC construction is safe without significant protective effects within 2 years following surgery.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Djaladat H, Ghoreifi A, Tejura T, et al. Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial. J Urol. 2024. PMID: 38620056. doi:10.1097/JU.0000000000003902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。